Atomoxetine (Strattera) for ADHD: risk of psychotic or manic symptoms
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a norepinephrine reuptake inhibitor used for the treatment of ADHD. These are the recommendations: Advice for healthcare professionals: • At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic […]
Varenicline psychiatric side effects: recommendations from the MHRA
The Medicines and Healthcare products Regulatory Agency has issued recommendations about the use of varenicline (Champix) as a smoking cessation drug. Advice for healthcare professionals: • Patients and their family or care-givers should be made aware of the possibility that trying to stop smoking might cause symptoms of depression • Patients who are taking varenicline […]